Table 1.
Clinicopathological characteristics of NSCLC patients in this study.
| Characteristics Platform | Training series | Testing series | GSE31210 HG-U133_Plus_2 | GSE3141 HG-U133_Plus_2 | |
|---|---|---|---|---|---|
| TCGA IlluminaHiSeq | GSE16025 GPL5106 | GSE27435 GPL8469 | |||
| Patients | 1014 | 71 | 42 | 246 | 111 |
| >60 | 721 | 51 | 21 | 124 | NA |
| ≤60 | 265 | 20 | 21 | 117 | NA |
| NA | 28 | 0 | 0 | 5 | NA |
| Gender | |||||
| Female | 406 | 49 | 12 | 130 | NA |
| Male | 608 | 22 | 30 | 116 | NA |
| Stage | |||||
| I | 518 | 42 | NA | 168 | NA |
| II | 283 | 16 | NA | 58 | NA |
| III | 168 | 13 | NA | 0 | NA |
| IV | 33 | 0 | NA | 0 | NA |
| NA | 12 | 0 | NA | 20 | NA |
| Survival | |||||
| Dead | 284 | 35 | 18 | 35 | 54 |
| Alive | 730 | 26 | 24 | 191 | 57 |
| NA | 0 | 0 | 0 | 20 | 0 |
NA, no information.